Locations:
Search IconSearch
August 27, 2020/Cancer

High-Volume Plasma Exchange in a Young COVID-19 Patient with Liver Failure

Bridge to transplant after acetaminophen overdose

650×450-Plasma

In June 2020, a 27-year-old woman developed a case of COVID-19; her main symptoms were stomach pain, nausea and diarrhea. To relieve the pain, she took so much acetaminophen that she had an overdose and developed fulminant liver failure.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

She was gravely ill and hospitalized at Cleveland Clinic in the COVID ICU. She was intubated and treated for symptoms of liver failure, which included cerebral edema.

To normalize her blood pressure, she was treated with high-dose vasopressors. The liver failure also caused a cytokine storm, which stressed her heart and kidneys. She was in need of a liver transplant but was considered too high risk. “Every moment, she was getting worse and further from being able to get a liver transplant,” says Kristin Ricci, MD, a transfusion medicine specialist and Medical Director of the apheresis unit at Cleveland Clinic.

High-volume plasma exchange administered

Cleveland Clinic is one of only a few medical centers worldwide able to perform high-volume plasma exchange. During the procedure, a patient’s plasma is removed with an apheresis instrument and is replaced with plasma from healthy donors. Unlike standard plasma exchange treatments, which treat a patient’s plasma once, high-volume plasma exchange treats it three to four times. This patient was the first at Cleveland Clinic treated with this approach; the goal was to stabilize her health so she could get a transplant.

The procedure was a team effort involving intensive care, hepatology, anesthesiology, liver transplant, nursing, apheresis, laboratory medicine and blood bank teams. “High-volume plasma exchange requires great resources and coordination. Many different groups used their strengths to save this patient’s life — Cleveland Clinic culture at its best,” says Dr. Ricci.

Advertisement

After the procedure, the patient became more hemodynamically stable, her vasopressor requirements decreased and many of her liver labs normalized. The procedure also removes inflammatory cytokines, so the storm subsided. Because of these major improvements, the patient was listed for a liver transplant.

The liver transplant team, led by Giuseppe D’Amico, MD, and Jacek Cywinski, MD, was ready to perform the transplant. The next day, the patient received a second high-volume plasma exchange which showed continued improvement in clinical status and labs. The transplant was performed that evening by a team that included more than 40 caregivers.

A life transformed

The patient had an uneventful recovery and has been discharged home and is doing well. “The high-volume plasma exchange was a game changer that saved her life. This technique completely changed the management strategy for this patient. We are excited about starting a program to use high-volume plasma exchange for acute liver failure,” says Cristiano Quintini, MD, Program Director and Surgical Director of the Liver Transplantation Program.

Advertisement

Related Articles

Interactive culinary medicine class
November 11, 2024/Cancer/Innovations
Integrative Oncology Improves Outcomes and Quality of Life

Combining mind, body and lifestyle practices in alignment with conventional cancer treatment

Pregnant woman
November 6, 2024/Cancer/News & Insight
Large Retrospective Study Finds Pregnancy Safe Among Young BRCA Carriers

Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Hurthle cell carcinoma
October 24, 2024/Cancer/News & Insight
Researchers Uncover Clues to Treating Rare Thyroid Cancer

Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Plan of care meeting
October 4, 2024/Cancer/Radiation Oncology
Five Years of Parallel Prospective Plan of Care Reviews

Radiation oncology department finds weekly plan of care meetings have multiple benefits

Ad